CAT-248

N/A

Report date: 2022/03/23 13:26:27

Base Information

Drug NameCAT-248

Drug Alias NameCAT248

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsAnti-CD70

TargetsCD70 antigen

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCatamaran Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesCatamaran Bio Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A